NASDAQ:PHASPhaseBio Pharmaceuticals Stock Price, Forecast & News

PhaseBio Pharmaceuticals' stock was trading at $3.13 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PHAS shares have increased by 92.0% and is now trading at $6.01. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PhaseBio Pharmaceuticals.

PhaseBio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for PhaseBio Pharmaceuticals.

PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) announced its earnings results on Tuesday, May, 12th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.10. The company had revenue of $0.32 million for the quarter, compared to analysts' expectations of $0.38 million. PhaseBio Pharmaceuticals had a negative return on equity of 70.50% and a negative net margin of 2,310.60%. View PhaseBio Pharmaceuticals' earnings history.

6 brokers have issued 12-month price targets for PhaseBio Pharmaceuticals' stock. Their forecasts range from $4.00 to $18.00. On average, they anticipate PhaseBio Pharmaceuticals' stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 116.3% from the stock's current price. View analysts' price targets for PhaseBio Pharmaceuticals.

Media coverage about PHAS stock has been trending positive recently, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. PhaseBio Pharmaceuticals earned a coverage optimism score of 2.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutPhaseBio Pharmaceuticals.

PhaseBio Pharmaceuticals saw a decline in short interest in April. As of April 30th, there was short interest totaling 2,490,000 shares, a decline of 10.1% from the April 15th total of 2,770,000 shares. Based on an average daily trading volume, of 277,500 shares, the short-interest ratio is currently 9.0 days. Approximately 17.9% of the shares of the stock are sold short. View PhaseBio Pharmaceuticals' Current Options Chain.

Some companies that are related to PhaseBio Pharmaceuticals include NewLink Genetics (NLNK), Passage Bio (IMRA), Emisphere Technologies (EMIS), BioDelivery Sciences International (BDSI), Beyondspring (BYSI), Xenon Pharmaceuticals (XENE), Neoleukin Therapeutics (NLTX), Protagonist Therapeutics (PTGX), Prothena (PRTA), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Flexion Therapeutics (FLXN), BioSpecifics Technologies (BSTC), Fulcrum Therapeutics (FULC) and Syros Pharmaceuticals (SYRS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Amarin (AMRN), Viking Therapeutics (VKTX), VBI Vaccines (VBIV), TapImmune (MRKR), Selecta Biosciences (SELB), Zynerba Pharmaceuticals (ZYNE) and Dynavax Technologies (DVAX).

(PHAS) raised $66 million in an initial public offering on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

PhaseBio Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (13.99%), BlackRock Inc. (3.44%), Ghost Tree Capital LLC (1.73%), DAFNA Capital Management LLC (1.11%), State Street Corp (0.87%) and Geode Capital Management LLC (0.75%). Company insiders that own PhaseBio Pharmaceuticals stock include Clay Thorp, John P Sharp, Jonathan P Mow, Linda Tufts, Michael York, Nancy J Hutson and Venture Advisors Iii Hatteras. View institutional ownership trends for PhaseBio Pharmaceuticals.

PHAS stock was sold by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC, Morgan Stanley, BlackRock Inc., UBS Group AG, and First Trust Advisors LP. View insider buying and selling activity for PhaseBio Pharmaceuticals.

PHAS stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Ghost Tree Capital LLC, Geode Capital Management LLC, State Street Corp, Sabby Management LLC, Wells Fargo & Company MN, Bank of New York Mellon Corp, and Nuveen Asset Management LLC. Company insiders that have bought PhaseBio Pharmaceuticals stock in the last two years include Clay Thorp, John P Sharp, Jonathan P Mow, Linda Tufts, Michael York, Nancy J Hutson, and Venture Advisors Iii Hatteras. View insider buying and selling activity for PhaseBio Pharmaceuticals.

Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PHAS stock can currently be purchased for approximately $6.01.

PhaseBio Pharmaceuticals has a market capitalization of $172.97 million and generates $2.36 million in revenue each year. The company earns $-39,250,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. PhaseBio Pharmaceuticals employs 40 workers across the globe.

The official website for PhaseBio Pharmaceuticals is www.phasebio.com.

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company can be reached via phone at 610-981-6500 or via email at [email protected]